Author of

• 20152

  +

  P1.03 - Chemotherapy/Targeted Therapy (ID 689)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22579

    +

    P1.03-024 - Efficacy of Carboplatin-Vinorelbine in Advanced NSCLC Patients at Persahabatan Hospital, Jakarta - Indonesia (ID 8426)

    09:30 - 16:00  |  Presenting Author(s): Putu Ayu Diah
    • Abstract

    Background:
    Combination of platinum-based and third generation drugs such as vinorelbine chemotherapy are frequently used as paliative chemotherapy for Non-small cell lung cancer (NSCLC) patients in Indonesia especially in Persahabatan Hospital. But there is still no data about the efficacy and tolerability of carboplatin-vinorelbine regimen. This study was conducted to evaluate the efficacy and toxicity of this regimen as first line chemotherapy for advanced NSCLC patients in Persahabatan Hospital.
    
    Method:
    This study was an observational study in advanced NSCLC patients who receive carboplatin-vinorelbine regimen as first line chemotherapy. subjects were recruited between 1[st] January 2015 to 30[th ]March 2017. Clinical data regarding the histological type, staging, side effect of chemotherapy, RECIST and survival were recorded.
    
    Result:
    Thirty eight subjects were recruited in this study of which carboplatin 5 AUC on day 1 and vinorelbine 30mg/m[2 ]on day 1 and 8 were administered as a combination therapy. This regimen has a good efficacy with overall response rate (ORR) 12,5% and clinical benefit rate (CBR) 87,5%. The overall survival (OS) 34,2% with median of survival time 387 days (12,9 moths) and progression free survival (PFS) 323 days (10,7 months). We found grade 1 anemia (38,4%) and grade 2 nausea vomiting (57,9%) as hematological and non-hematological toxicity that frequently occured in this study. Two cases of grade 2 gastrointestinal bleeding were observed but the subjects still be able to continue the chemotherapy soon after recovery. Mild phlebitis were observed in 65.7% cases ( 24 subjects) and moderate phlebitis in 2.6% (1 subject) as procedural complication of this chemotherapy regimen.
    
    Conclusion:
    Combination of carboplatin and vinorelbine as first line chemotherapy has a good efficacy and tolerability for advanced NSCLC subjects.